Eli Lilly makes transparency vow

Eli Lilly

With all the talk about big pharma paying physicians for this or that, Eli Lilly is taking on the role of industry forerunner. In a proactive move, the pharma giant says it will start to become transparent about just how much cash it doles out to physicians and for what purpose.

Perhaps with more and more members of Congress setting a disclosure bill in motion, Lilly decided to come face to face with what might be inevitable. Regardless of what happens, it's a decent PR move and pharma companies definitely need good PR these days.   

Specifically, Lilly will disclose how much it pays individual physicals for advisory roles, speeches and other services, as long as the payments are more than $500. The listing will be on a public database. However, Lilly will not be disclosing payments to physicians for travel, gifts and entertainment at this time. 

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

- here's Lilly's release

Read more on

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.